Cancer immunotherapies targeting immune checkpoints have improved the outcomes of various cancers.[21] PD-L1 is a key regulator of immune response.[22] The PD-L1 expression is positively correlated with the clinical outcomes. This evidence concerns the gene CD274 and cancer.